首届东盟医疗器械圆桌会议与单一递交模式（2026-09-09）

1. Key takeaway

On 9 September 2026, the first ASEAN Medical Device Roundtable was held in Kuala Lumpur, hosted by the Malaysian Medical Device Authority (MDA) and chaired by Malaysia’s Minister of Health. Participants included Brunei, Cambodia, Laos, Myanmar, Thailand, Vietnam, Timor-Leste, Indonesia and the Philippines.

The core outcome was that the participating countries agreed in principle to advance, in phases, a Single Submission Model for pre-market approval of medical devices, with Malaysia proposed as the coordination entry point for distributing technical dossiers. Follow-up: the ASEAN Medical Device Committee and the ASEAN Secretariat are to develop the implementation mechanism, with progress expected before the committee meeting in Vientiane, Laos, on 6 to 8 October 2026.

Key boundary: each country retains the final registration decision under its own law.

GRZAN note: the meeting was held on 9 September 2026 (Kuala Lumpur); the next milestone is 6 to 8 October 2026 (AMDC meeting in Vientiane, Laos); the mechanism changes the dossier entry point, not the decision-making power.

2. Regulatory basis

3. Expert commentary

1. This development changes the ”entry point”, not the ”decision-making power”. The most common misreading is that ”in future one submission to ASEAN will be valid across the whole region”. The reporting states explicitly that each country retains the final registration decision. Until the mechanism is in place, Cambodia still requires a separate submission country by country.

1. CSDT is the technical prerequisite of this mechanism — which is why this series keeps insisting on CSDT-format dossiers. The essence of the Single Submission Model is that a coordination entry point collects technical dossiers centrally and distributes them to the countries. A dossier not organised to CSDT cannot enter this flow. Conversely, every dossier prepared to CSDT now is an asset that can be reused directly in the future.

1. Cambodia is in the regional mechanisms but not yet in the recognition network. For comparison: the Malaysian Medical Device Authority and the Thai FDA signed a confidentiality agreement at the 29th GHWP annual meeting on 4 December 2025, piloted a reliance scheme from 1 February to 30 April 2026, and jointly announced on 1 May 2026 its full implementation for Class B, C and D devices (both Malaysia–Singapore recognition and Malaysia–Thailand reliance are now in force). Cambodia is currently not party to these bilateral arrangements (grade B). This means that for the foreseeable future Cambodia remains a market where the national procedure must be completed in full, on its own.

4. Practical recommendations

1. Treat ASEAN multi-country registration as ”one dossier plus multiple submissions”, not ”one dossier per country”. Use the CSDT as the master dossier and make country-specific additions and deletions on that basis.
2. When scheduling multiple countries, plan Cambodia outside the recognition network with its own timeline. Do not assume that obtaining a Malaysian or Thai certificate will speed up Cambodia — although reference-market evidence helps review, there is no recognition channel.
3. Track the follow-up outcomes of the October 2026 AMDC meeting in Vientiane. The details of the implementation mechanism will take shape in this series of meetings — the key window for judging when the Single Submission Model will land.

5. Verification checklist

• □ Understood that the Single Submission Model changes the dossier entry point, not the decision-making power
• □ Confirmed that Cambodia is not part of the Malaysia–Singapore or Malaysia–Thailand recognition/reliance arrangements
• □ Technical dossier organised to CSDT and reusable in future
• □ Cambodia’s timeline modelled separately in multi-country scheduling
• □ The October 2026 AMDC meeting in Vientiane added to the tracking list
• □ Clients informed that ”country-by-country registration continues until the mechanism is in place”

Regulatory information verified as of 29 October 2026.

In Southeast Asia, GRZAN’s core capabilities focus on three areas. First, tracking the legislative progress of dedicated medical device laws across member states — Singapore, Malaysia, Thailand, Indonesia, the Philippines and Vietnam have each established written device regulatory frameworks, whereas Cambodia still has no dedicated Medical Device Law. The current rules are assembled from three layers: the legal basis for registration numbers provided by the 1996 Law on the Management of Pharmaceuticals and its 2007 amendment, the classification and procedures provided by Prakas No. 1258 of 2012, and the technical framework of the ASEAN Medical Device Directive. Regulatory certainty is therefore markedly lower than in markets that have completed legislation. Second, local authorised representative services: GRZAN may act as the manufacturer’s statutory representative in Cambodia, carrying registration submissions, regulatory communication and post-market reporting obligations, and assisting with the practical implementation of the Cambodian registered pharmacist and pharmaceutical import/export enterprise licence requirements. Third, quality system and testing support: assisting with the establishment of a quality management system meeting ISO 13485 requirements, and organising the technical dossier in accordance with the ASEAN Common Submission Dossier Template (CSDT).

Business enquiries: info@grzanglobal.com